Lupin said that the US Food and Drug Administration (FDA) has wrapped up a pre-approval and GMP inspection of its API manufacturing plant in Visakhapatnam, Andhra Pradesh.

The FDA inspection was undertaken from 6 March to 10 March 2023 and was completed without any observations.

Nilesh Gupta — Lupin Managing Director said: “We are pleased with the successful completion of the inspection at our Vizag facility.

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all.”

  Andhra Pradesh, Lupin, Nilesh Gupta, US FDA, US Food and Drug Administration, Visakhapatnam